Find a Trial

Trial Summary


Protocol No.CTO-NP-G2-044-P2-01
StatusOPEN TO ACCRUAL
Principal InvestigatorJalal, Shadia
ScopeNational
PhasePhase I/II
Age GroupAdult
TitleNP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
DescriptionMulticenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-(L)1 therapy.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Have a histopathologically confirmed advanced or metastatic solid tumor malignancy that is either treatment-refractory or otherwise ineligible for treatment with standard of care agents/regimens; and Have measurable disease per RECIST 1.1.
  • Life expectancy of >6 months
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632
    Email: iutrials@iu.edu